Results 41 to 50 of about 12,580 (199)

Evaluation of Nephrotoxic Properties of Favipiravir Using the RPTEC cell model

Безопасность и риск фармакотерапии, 2023
Scientific relevance. Favipiravir is an antiviral RNA polymerase inhibitor used to treat COVID-19. An adverse drug reaction associated with the use of favipiravir is renal disorder.Aim.
V. A. Evteev, I. S. Semenova, N. D. Bunyatyan, A. B. Prokofiev   +3 more
doaj   +1 more source

Theoretical Insights into the Effect of Halogenated Substituent on the Electronic Structure and Spectroscopic Properties of the Favipiravir Tautomeric Forms and Its Implications on the Treatment of COVID-19

, 2020
In this study, we systematically investigated the electronic structure, spectroscopic (nuclear magnetic resonance, infrared, Raman, electron ionization mass spectrometry, UV-Vis, circular dichroism, and emission) properties, and tautomerism of ...
Felipe, La Porta, Teodorico, Ramalho, Letícia, Assis, Alexandre A., de Castro, João Paulo A., de Jesus   +4 more
core   +1 more source

When antivirals backfire: An evaluation of favipiravir’s clinical outcomes in critically ill patients with COVID-19: A multicenter cohort study

Journal of Infection and Public Health, 2023
Background: Favipiravir is an oral antiviral, that might treat COVID-19 by enhancing viral eradication, particularly in patients with mild-to-moderate disease.
Khalid Al Sulaiman, Ohoud Aljuhani, Ghazwa B. Korayem, Ali F. Altebainawi, Mashael AlFaifi, Majed Nahari, Alaa Almagthali, Abrar K. Thabit, Raghad Alhajaji, Reham Alharbi, Khawla Kahtani, Abeer A. Alenazi, Aisha Alharbi, Munirah M. Alghwainm, Sara M. Alotaibi, Yazeed S. Alghamdi, Samar Alotaibi, Shaden H. Alonazi, Jumanah M. Almutairi, Ramesh Vishwakarma   +19 more
doaj   +1 more source

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia

International Journal of Infectious Diseases, 2023
Objectives: To evaluate the efficacy and safety of nafamostat combined with favipiravir for the treatment of COVID-19. Methods: We conducted a multicenter, randomized, single-blind, placebo-controlled, parallel assignment study in hospitalized patients ...
Mahoko Ikeda, Shu Okugawa, Kosuke Kashiwabara, Takashi Moritoyo, Yoshiaki Kanno, Daisuke Jubishi, Hideki Hashimoto, Koh Okamoto, Kenji Tsushima, Yasuki Uchida, Takahiro Mitsumura, Hidetoshi Igari, Takeya Tsutsumi, Hideki Araoka, Kazuhiro Yatera, Yoshihiro Yamamoto, Yuki Nakamura, Amato Otani, Marie Yamashita, Yuji Wakimoto, Takayuki Shinohara, Maho Adachi-Katayama, Tatsunori Oyabu, Aoi Kanematsu, Sohei Harada, Yuichiro Takeshita, Yasutaka Nakano, Yasunari Miyazaki, Seiichiro Sakao, Makoto Saito, Sho Ogura, Kei Yamasaki, Hitoshi Kawasuji, Osamu Hataji, Jun-Ichiro Inoue, Yasuyuki Seto, Kyoji Moriya   +36 more
doaj   +1 more source

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.: Favipiravir pharmacokinetics in non-human primates

, 2016
International audienceFavipiravir is a RNA polymerase inhibitor that showed a strong antiviral efficacy in vitro and in small animal models of several viruses responsible for hemorrhagic fever (HF) including Ebola virus.
Yamada, Koichi, Raoul, Hervé, Nguyen, Thi Huyen Tram, Jacquot, Frédéric, Guedj, Jérémie, Mentré, France, Oestereich, Lisa, Taburet, Anne-Marie, Kadota, Takumi, de Lamballerie, Xavier, Madelain, Vincent   +10 more
core   +1 more source

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia

Frontiers in Medicine, 2022
ObjectivesThere are limited data on the efficacy and safety of favipiravir antiviral in coronavirus disease 2019 (COVID-19), particularly in the more progressed disease phase.
Saleh Al-Muhsen, Nouf S. Al-Numair, Narjes Saheb Sharif-Askari, Roaa Basamh, Banan Alyounes, Amjad Jabaan, Fatemeh Saheb Sharif-Askari, Mohammed F. Alosaimi, Fahad Alsohime, Rabih Halwani, Rabih Halwani, Rabih Halwani, Haya Al-Saud, Haya Al-Saud   +13 more
doaj   +1 more source

Adverse effects associated with favipiravir in patients with COVID-19 pneumonia: a retrospective study

São Paulo Medical Journal, 2022
BACKGROUND: Favipiravir is generally used in treating coronavirus disease 2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of favipiravir and whether it is a good treatment option.
Figen Öztürk Ergür, Murat Yıldız, Melahat Uzel Şener, Suna Kavurgacı, Ayperi Ozturk   +4 more
doaj   +1 more source

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

, 2018
BackgroundDespite repeated outbreaks, in particular the devastating 2014–2016 epidemic, there is no effective treatment validated for patients with Ebola virus disease (EVD).
Raoul, Hervé, Stephan Gunther (5018402), Jacquot, Frédéric, Géraldine Piorkowski (800529), France Mentré (238333), Gunther, Stephan, Géraldine Piorkowski, Piorkowski, Géraldine, Caroline Carbonnelle, Xavier de Lamballerie, Stephan Gunther, Carbonnelle, Caroline, France Mentré, Anne Rodallec (3776029), Mentré, France, Caroline Carbonnelle (2549053), Anne Rodallec, Thi Huyen Tram Nguyen, Thi Huyen Tram Nguyen (3776035), Hervé Raoul (288207), Nguyen, Thi Huyen Tram, Jérémie Guedj (2549236), Vincent Madelain, Rodallec, Anne, de Lamballerie, Xavier, Madelain, Vincent, Xavier de Lamballerie (95840), Vincent Madelain (3776032), Hervé Raoul, Guedj, Jérémie, Frédéric Jacquot (2825714), Jérémie Guedj, Frédéric Jacquot   +32 more
core   +1 more source

Favipiravir

Reactions Weekly, 2022
  +7 more sources

Simultaneous Determination of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) and Favipiravir in Human Plasma by HPLC-MS/MS

Разработка и регистрация лекарственных средств, 2023
Introduction. Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus (severe acute respiratory syndrome-related coronavirus 2).
T. N. Komarov, P. K. Karnakova, O. A. Archakova, D. S. Shchelgacheva, N. S. Bagaeva, I. E. Shohin, K. Ya. Zaslavskaya, P. A. Bely   +7 more
doaj   +1 more source